Zentalis Pharmaceuticals (NASDAQ:ZNTL) Given New $6.00 Price Target at Wells Fargo & Company

Zentalis Pharmaceuticals (NASDAQ:ZNTL) had its price objective decreased by analysts at Wells Fargo & Company from $8.00 to $6.00 in a report issued on Thursday,Benzinga reports. The firm currently has an “equal weight” rating on the stock. Wells Fargo & Company‘s price objective suggests a potential upside of 261.45% from the stock’s previous close.

A number of other research firms have also weighed in on ZNTL. HC Wainwright dropped their price target on shares of Zentalis Pharmaceuticals from $20.00 to $10.00 and set a “buy” rating on the stock in a research report on Wednesday. Wedbush restated a “neutral” rating and issued a $4.00 target price on shares of Zentalis Pharmaceuticals in a research note on Friday, January 24th. UBS Group decreased their price target on Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating for the company in a research report on Tuesday. Finally, Guggenheim reduced their price objective on Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating for the company in a research note on Friday, November 15th. Five investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat, Zentalis Pharmaceuticals has a consensus rating of “Hold” and an average price target of $8.24.

Zentalis Pharmaceuticals Stock Down 12.2 %

Shares of ZNTL traded down $0.23 during midday trading on Thursday, hitting $1.66. The company’s stock had a trading volume of 3,656,997 shares, compared to its average volume of 2,910,479. Zentalis Pharmaceuticals has a one year low of $1.66 and a one year high of $18.07. The stock has a market capitalization of $118.29 million, a price-to-earnings ratio of -0.67 and a beta of 1.86. The company’s fifty day simple moving average is $3.00 and its two-hundred day simple moving average is $3.30.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last released its earnings results on Tuesday, November 12th. The company reported ($0.56) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.36. On average, research analysts predict that Zentalis Pharmaceuticals will post -2.48 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Erste Asset Management GmbH bought a new stake in Zentalis Pharmaceuticals during the 3rd quarter valued at $37,000. Paloma Partners Management Co purchased a new position in shares of Zentalis Pharmaceuticals in the third quarter valued at about $37,000. Aigen Investment Management LP bought a new position in shares of Zentalis Pharmaceuticals during the third quarter valued at about $41,000. Capstone Investment Advisors LLC bought a new position in shares of Zentalis Pharmaceuticals during the third quarter valued at about $48,000. Finally, China Universal Asset Management Co. Ltd. boosted its holdings in shares of Zentalis Pharmaceuticals by 63.9% during the third quarter. China Universal Asset Management Co. Ltd. now owns 13,676 shares of the company’s stock worth $50,000 after purchasing an additional 5,333 shares during the period.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.